Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage IIIB-C and Stage IV Melanoma (CheckMate 238): 4-year Results From a Multicentre, Double-blind, Randomised, Controlled, Phase 3 TrialLancet Oncol 2020 Sep 18;[EPub Ahead of Print], PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, CL Cowey, M Schenker, JJ Grob, V Chiarion-Sileni, I Márquez-Rodas, MO Butler, M Maio, MR Middleton, L de la Cruz-Merino, P Arenberger, V Atkinson, A Hill, LA Fecher, M Millward, NI Khushalani, P Queirolo, M Lobo, V de Pril, J Loffredo, J Larkin, J Weber
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.